The free image of an eye for the header of today’s offering is courtesy of ClipArt and Google Images.

Health Friday is a series devoted to information about Big Pharma, vaccines, general health, and associated topics. There are Important Notifications from our host, Wolf Moon; the Rules of our late, good Wheatie; and, certain caveats from Yours Truly, of which readers should be aware. They are linked here. Note: AI-generated items in today’s offering will be cited as such. If readers wish to post AI-generated items in today’s discussion thread, they must cite their source. Thank You.

ER-100: SV40 Injected into the Eyes to “Reverse Aging”: Part One of Two

There is a certain tenured PhD professor in genetics at Harvard University. His name is David A. Sinclair. He is a native of Australia. Dr. Sinclair, and his lab at Harvard, specialize in the study of what ages human beings. He also studies methods and ways to slow down, or even to stop, this aging process. He is the holder of numerous Patents in this regard. Please see: https://sinclair.hms.harvard.edu/people/david-sinclair. Dr. Sinclair is also the co-founder of a company called Life Biosciences. The company’s statement: “At Life Biosciences, we are on a mission to reverse age-related disease” (https://www.lifebiosciences.com/about-us/about-life-sciences/.) Today’s offering is not to be viewed in any way as a “hit piece” on Dr. Sinclair, or to denigrate his work: instead, it is to present another take on a certain project that he is working on.

Dr. Sinclair believes that he can reverse aging of the human eye (and also, by extension, the mechanisms of human eyesight.) He has been doing research on this subject since before the year 2020. This current year, 2026, Dr. Sinclair, via Life Biosciences, secured $80 Million dollars in funding to put his theories and research into action (https://allsci.com/news/funding/life-biosciences-secures-usd-80-million-series-d-to-advance-er-100-gene-therapy/, 9 April 2026.) The drug that would be used to reverse the aging of the human eye is called ER-100. It is injected into the eyes. ER-100 is immediately hailed as a “breakthrough” drug: including by the alternative COVID-19 treatment entity, Independent Medical Alliance (https://sashalatypova.substack.com/p/dr-ryan-cole-and-independent-medical, “Dr. Ryan Cole and Independent Medical Alliance are now promoting an “immortality elixir” containing and known carcinogen, synthetic SV40!”, 26 June 2026.) Also, in January 2026, Life Biosciences secured an FDA clearance for the drug’s IND application for ER-100 (https://www.lifebiosciences.com/life-biosciences-announces-fda-clearance-of-ind-application-for-er-100-in-optic-neuropathies/, 28 January 2026. IND = Investigational New Drug.) Perhaps predictably, this announcement was heralded as a kind of “turning point” for the FDA: https://lifespan.io/life-bios-trial-is-the-fda-warming-to-rejuvenation/, “Life Bio’s Trial: Is the FDA Warming to Rejuvenation?”, Steve Hill, 8 April 2026.

However — the Life Biosciences press release, cited above, mentions only three of the four “Yamanaka factors” that ER-100 would be be utilizing. This is not a small point. And this is where the story gets interesting.

Dr. Shinya Yamanaka (https://en.wikipedia.org/wiki/Shinya_Yamanaka) discovered proteins, called Transcription Factors, which regulate / control “…the rate of transcription of genetic information from DNA to messenger RNA [mRNA], by binding to DNA sequences” (https://en.wikipedia.org/wiki/Transcription_factor.) Dr. Yamanaka reduced the original number of Transcription Factors from twenty-four down to four: OCT-4; SOX-2; KLF-4; and, c-Myc. It is the c-Myc transcription factor that can “go rogue”, so to speak, and foster the growth of cancer cells: https://www.nature.com/articles/nrc904, “c-MYC: more than just a matter of life and death”, Stella Pelengaris, et al. A screenshot of the Abstract of this article is below:

What is SV40 — the element that has been proven to be in both the Pfizer-BioNTech and in the Moderna modRNA COVID-19 bioweapon “vaccines”? Please see:https://doi.org/10.1093/jnci/91.2.119, “Cell and Molecular Biology of Simian Virus 40: Implications for Human Infections and Disease”, Janet S. Butel, John A. Lednicky; 20 January 1999. Following is a quotation from the Abstract of this paper: “Simian virus 40 (SV40), a polymavirus of rhesus macaque origin, was discovered in 1960 as a contaminent of polio vaccines that were distributed to millions of people from 1955 to early 1963. SV40 is a potent DNA tumor virus that induces tumors in rodents and transforms many types of cells in culture, including those of human origin.” (Bolding mine.)

Why is Yours Truly including a mention of SV40 here? Because SV40 is contained in ER-100. It is the “swapped-out” protein for the fourth Yamanaka Factor, c-Myc, discussed above. The following screenshot, below, is from the Latypova article on ER-100: a screenshot from the 2020 published paper by Dr. David Sinclair, et al. (which will be further discussed in Part Two.) It is also, in Yours Truly’s opinion, the reason why the Life Biosciences press release, cited above, mentions only three of the Yamanaka Factors — it is possible that the company does not want the public to know that SV40, a cancer-causing protein, is contained in the drug: especially in light of the fact that more people are starting to realize that SV40 is in the modRNA COVID-19 bioweapon “vaccines” that they have in their bodies:

In other words: the poly(A) “signal” used in the modified AAV-TRE-OSK element in ER-100 is the SV40 poly(A) “signal.” AAV is “adeno-associated virus vector” element; TRE is the tetracycline-derived element; OSK is the acronym for the three Yamanaka Factors OCT-4, SOX-2, and KLF-4 elements. Thus far, then, ER-100 is comprised of AAV (with the SV40 poly(A) tail) + TRE + OSK-4 + SOX-2 + KLF-4. But this is not the entire story. Yours Truly now turns to the Patent “template” for ER-100, which was “invented” by Dr. David A. Sinclair, et al., Patent Number WO2020/069373, filed on 27 September 2019.

The Patent information for WO2020/069373 is found here: https://patentscope.wipo.net/search/en/WO2020069373. The Patent was filed using an international listing, as opposed to a US Patent listing. The International Filing Date was 27 September 2019. The Publication Date was 2 April 2020. The applicamts for the Patent were the President and Fellows of Harvard College, 17 Quincy St., Cambridge, MA, 02138. The funding for the research leading to the Patent was provided through NIAID grants R01AG019719, and R01DK100263. The Title of the Patent is: “1.WO2020069373 – CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION.” The following are Yours Truly’s summaries of some of the listings in the Description of the Patent:

Section 0002: Lists the NIAID grants that funded the “invention.”

Section 0018: mention of SV40: an “expression vector”, also as a “constitutive promoter.”

Section 0019: SV40 amounts used in the composition of the “invention.” These amounts range from AT LEAST 70%, up to 100% “in certain embodiments.”

Section 0033: the “invention” will contain a tetracycline (example: doxycyline.)

Section 0034: the “invention” may include TRE (a Tetracycline Reverse Element (a promoter.))

Section 0035: areas of the body where the “invention” can be used. Examples: eye; ear; nose; mouth; bone; breast; lung; pancreas; cardiac muscle; liver; skin; heart; intestine; testis; ovary.

**** Section 0047: the “compositions” of the “invention” may include “any of the recombinant viruses” (e.g. alphavirus; vaccinia virus; herpes virus; AAV; etc.)

Section 0074: types of ocular diseases the “invention” can be used for.

Section 00109: description of the Gain-of-Function techniques used to produce the “invention.” Section 00100 and Section 00111 further describe the Gain-of-Function techniques used.

Section 00133: the “invention” can also use a “tetracycline-controlled transactivator” called MUTANT REVERSE TETRACYCLINE.

Section 00200: the “invention” will use a nanoparticle called NANOPLASMID. (For more information on NANOPLASMID, please see: https://www.aldevron.com/custom-manufacturing/nanoplasmid/faq.)

Section 00263: start of listings of the “engineered nucleic acids”, “engineered cells”, “engineered proteins”, and “chemical agents” that the “invention” will use to induce “expression” of the OCT-4, KFL-4, and/or the SOX-2 factors cells.

Section 00294: start of discussion and listings of the various cationic lipids that the “invention” will use in “certain embodiments.” Examples: Lipofectin (DOTMA + DOPE); DOTMA separately; DOSPA; DDAB, etc.

Now, from the above, thus far, ER-100 is comprised of: AAV (with the SV40 poly(A) tail) + TRE (Tetracycline Reverse Element promoter) + OSK-4 + SOX-2 + KFL-4 + possibly “any of the recombinant viruses (Section 0047) + a MUTANT REVERSE TETRACYCLINE TRANSACTIVATOR FOR EXPRESSION OF GENES (Section 00133) + NANOPLASMID (Section 00200) + a cationic lipid (Section 00294.)

It also appears, in Yours Truly’s opinion, that ER-100 for use to “reverse aging in the eye” may be only the first application of Dr. Sinclair’s “invention.” It appears that the “certain embodiments” of his “invention” can potentially be used to “reverse the aging” of many areas and organs of the human body.

To be continued in Part Two.

Peace, Good Energy, Respect: PAVACA

(Intellectual Disclaimer and Notice: Except for the linked URLs and other items in today’s offering that are available on the Internet, the ideas and/or opinions in today’s offering are by PAVACA (M.E. Forbes, aka M.E.C. Forbes.) Credit must be given to PAVACA if ideas and/or opinions in today’s offering are used by other blog writers; by podcasters; or in print or social media.)